Suppr超能文献

感染基孔肯雅病毒后早期持续性肌肉骨骼疼痛和关节炎患者中氯喹的疗效和炎症细胞因子反应。

Effectiveness of chloroquine and inflammatory cytokine response in patients with early persistent musculoskeletal pain and arthritis following chikungunya virus infection.

机构信息

Center for Rheumatic Diseases, Pune, India.

出版信息

Arthritis Rheumatol. 2014 Feb;66(2):319-26. doi: 10.1002/art.38221.

Abstract

OBJECTIVE

To evaluate whether chloroquine (CQ) is more effective than meloxicam for treating early musculoskeletal pain and arthritis following acute chikungunya (CHIK) virus infection.

METHODS

During the 2006 CHIK epidemic, 509 rural community cases of acute CHIK virus infection were identified in the district of Sholapur in India. Seventy consenting adult patients (seropositive for IgM/IgG anti-CHIK antibody) with early persistent musculoskeletal pain and arthritis were randomized into a 24-week, 2-arm, parallel efficacy trial of CQ (250 mg/day) and meloxicam (7.5 mg/day). Assessors completed a rheumatology evaluation in a blinded manner and collected blood samples in the patients' homes, as per protocol. Laboratory parameters included serum cytokine assay (interleukin-6 [IL-6], interferon-γ [IFNγ], tumor necrosis factor α, CXCL10/IFNγ-inducible protein 10, and IL-13). Twenty-two patients who failed to meet the eligibility criteria (low pain cohort) were also followed up with similar evaluations. An intent-to-treat analysis was completed. At baseline, the 2 groups (38 patients randomized to receive CQ and 32 patients randomized to receive meloxicam) were well matched.

RESULTS

There were no significant efficacy differences between the meloxicam group and the CQ group (mean changes in the visual analog scale score for pain -3.9 and -4.2, respectively). Patients improved significantly. Cytokine levels remained several-fold increased, were disproportionate to the clinical response, and were not different from those in the low pain cohort. Seven patients withdrew. Adverse events were mild and infrequent.

CONCLUSION

This exploratory community intervention trial failed to identify an advantage of CQ over meloxicam to treat early musculoskeletal pain and arthritis following acute CHIK virus infection, but therapeutic efficacy of CQ was not ruled out. The inflammatory cytokine response was intense and was not consistent with clinical status.

摘要

目的

评估氯喹(CQ)是否比美洛昔康更有效治疗急性基孔肯雅热(CHIK)病毒感染后早期肌肉骨骼疼痛和关节炎。

方法

在 2006 年 CHIK 疫情期间,印度绍拉普尔区发现了 509 例农村社区急性 CHIK 病毒感染病例。70 名同意参加的成年患者(抗 CHIK 病毒 IgM/IgG 抗体血清阳性)出现早期持续性肌肉骨骼疼痛和关节炎,随机分为 CQ(250mg/天)和美洛昔康(7.5mg/天)24 周 2 臂平行疗效试验组。评估员按照方案在患者家中以盲法进行风湿病评估并采集血样。实验室参数包括血清细胞因子测定(白细胞介素-6[IL-6]、干扰素-γ[IFNγ]、肿瘤坏死因子-α、CXCL10/IFNγ诱导蛋白 10 和 IL-13)。22 名不符合入选标准的患者(低痛组)也进行了类似的评估。完成意向治疗分析。基线时,2 组(38 名随机接受 CQ 治疗的患者和 32 名随机接受美洛昔康治疗的患者)匹配良好。

结果

美洛昔康组和 CQ 组之间无显著疗效差异(疼痛视觉模拟评分的平均变化分别为-3.9 和-4.2)。患者显著改善。细胞因子水平仍增加数倍,与临床反应不成比例,与低痛组无差异。7 名患者退出。不良事件轻微且罕见。

结论

这项探索性社区干预试验未能确定 CQ 治疗急性 CHIK 病毒感染后早期肌肉骨骼疼痛和关节炎优于美洛昔康,但不能排除 CQ 的治疗效果。炎症细胞因子反应强烈,与临床状态不一致。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验